C
Clemens M. Wendtner
Researcher at Ludwig Maximilian University of Munich
Publications - 118
Citations - 16544
Clemens M. Wendtner is an academic researcher from Ludwig Maximilian University of Munich. The author has contributed to research in topics: Chronic lymphocytic leukemia & Fludarabine. The author has an hindex of 37, co-authored 106 publications receiving 13614 citations. Previous affiliations of Clemens M. Wendtner include University of Calgary & University of Bonn.
Papers
More filters
Journal ArticleDOI
Virological assessment of hospitalized patients with COVID-2019.
Roman Wölfel,Victor M. Corman,Wolfgang Guggemos,M Seilmaier,Sabine Zange,Marcel A. Müller,Daniela Niemeyer,Terry Jones,Terry Jones,Patrick Vollmar,Camilla Rothe,Michael Hoelscher,Tobias Bleicker,Sebastian Brünink,Julia Schneider,Rosina Ehmann,Katrin Zwirglmaier,Christian Drosten,Clemens M. Wendtner +18 more
TL;DR: Detailed virological analysis of nine cases of coronavirus disease 2019 (COVID-19) provides proof of active replication of the SARS-CoV-2 virus in tissues of the upper respiratory tract.
Journal ArticleDOI
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
Michael Hallek,Kirsten Fischer,Günter Fingerle-Rowson,Anna-Maria Fink,Raymonde Busch,Jiří Mayer,Manfred Hensel,Georg Hopfinger,G D Hess,U. Von Grünhagen,Matthias Bergmann,John Catalano,Pier Luigi Zinzani,Federico Caligaris-Cappio,John F. Seymour,Alain Berrebi,Ulrich Jäger,Bruno Cazin,Marek Trneny,Anne Westermann,Clemens M. Wendtner,Barbara Eichhorst,Peter Staib,Andreas Bühler,Dirk Winkler,Thorsten Zenz,S Böttcher,Matthias Ritgen,Myriam Mendila,Michael Kneba,Hartmut Döhner,Stephan Stilgenbauer +31 more
TL;DR: Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab improves progression-free survival and overall survival in patients with chronic lymphocytic leukaemia, and the results suggest that the choice of a specific first-line treatment changes the natural course of chronic lymphocytes.
Journal ArticleDOI
Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
Valentin Goede,Kirsten Fischer,Raymonde Busch,Anja Engelke,Barbara Eichhorst,Clemens M. Wendtner,Tatiana Chagorova,Javier de la Serna,Marie-Sarah Dilhuydy,Thomas Illmer,Stephen Opat,Carolyn Owen,Olga Samoylova,Karl-Anton Kreuzer,Stephan Stilgenbauer,Hartmut Döhner,Anton W. Langerak,Matthias Ritgen,Michael Kneba,Elina Asikanius,Kathryn Humphrey,Michael Wenger,Michael Hallek +22 more
TL;DR: Combining an anti-CD20 antibody with chemotherapy improved outcomes in patients with CLL and coexisting conditions, and obinutuzumab was superior to rituximab when each was combined with chlorambucil.
Journal ArticleDOI
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study
Stephan Stilgenbauer,Barbara Eichhorst,Johannes Schetelig,Steven Coutre,John F. Seymour,Talha Munir,Soham D. Puvvada,Clemens M. Wendtner,Andrew W. Roberts,Wojciech Jurczak,Stephen P. Mulligan,Sebastian Böttcher,Mehrdad Mobasher,Ming Zhu,Monali Desai,Brenda Chyla,Maria Verdugo,Sari H. Enschede,Elisa Cerri,Rod A. Humerickhouse,Gary Gordon,Michael Hallek,William G. Wierda +22 more
TL;DR: Results of this trial show that venetoclax monotherapy is active and well tolerated in patients with relapsed or refractory del(17p) chronic lymphocytic leukaemia, providing a new therapeutic option for this very poor prognosis population.
Journal ArticleDOI
Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia.
Barbara Eichhorst,Raymonde Busch,Georg Hopfinger,Rita Pasold,Manfred Hensel,Cordelia Steinbrecher,Siegfried Siehl,Ulrich Jäger,Manuela Bergmann,Stephan Stilgenbauer,Carmen D. Schweighofer,Clemens M. Wendtner,Hartmut Döhner,Günter Brittinger,Bertold Emmerich,Michael Hallek +15 more
TL;DR: First-line treatment with FC increases the response rates and the treatment-free interval in younger patients with advanced CLL and no difference in median overall survival has been observed.